In 2019, the National Institute of Healthcare Data Science at Nanjing University was established to pursue multidisciplinary collaboration and research. The institute consists of three platforms, the big-data and artificial intelligence platform from the school of computer science, the clinical trials platform from the school of medicine and the translational medicine and international collaboration platform from the school of business. By 2021, the clinical trials platform runs two major clinical trials groups, the Chinese Acute Pancreatitis Clinical Trials Group(CAPCTG) and the Chinese Critical Care Nutrition trials Group(CCCNTG), both dedicating to organizing nationwide trials across China. Since the inception of the research network, we have conducted several multi-center randomized controlled trials involving more than 100 participating sites and thousands of patients. With the progressive integration of the three platforms, we aimed to share our expertise and improve future clinical practice with our high-quality trials and data mining techniques.
BSc MD PhD (H:24; Pubs: 170; C: 2160; patents: 14)
Prof Li is a Yangtze River Scholar and the Director of the Department of Critical Care Medicine, Jinling Hospital and Co-director of National institute of Healthcare Data Science at Nanjing University. As a surgeon and intensivist, Prof Li was among the first group of doctors dispatched to Wuhan. He worked as a section chief at Huoshenshan Hospital, (Field hospital built in 7 days to treat critically-ill COVID-19 patient). As the Co-chair of the Chinese Society of Critical Medicine, Prof Li found the Chinese critical care nutrition trials group (CCCNTG) to study nutritional therapy in critically ill patients
Being Part of the International Research Community Looking back at the year 2023, the Chinese Acute Pancreatitis Clinical Trials Group and the Chinese Critical Care Nutrition Trials Group (CAPCTG & CCCNTG) had made great progress in the development of high-quality clinical trials. The......
08 February, 2024
Special statement Sample size expansion of the ESSENTIAL trial Considering the latest findings in the EFFORT-Protein trial that higher protein delivery might be harmful to patients with AKI, the ESSENTIAL trial revised the eligible criteria on March 4th 2023, expanding the exclusion criteria......
01 February, 2024
On May 29, 2023, the kick-off meeting for “The EFFect Of high pRotein versus usual care on clinical, muscle, physical function and quality of life outcomes in critically ill patienTs (EFFORT-outcomes)” was successfully carried out. Professor Daren Heyland from Queen’s University, Professor Zheng Yii Lee from the......
01 June, 2023the Atlanta classification of acute pancreatitis enables the standardization of related research reports and facilitates the communication...
clinical guidelines for the diagnosis and treatment of severe acute pancreatitis (SAP) are contained in this opinion paper published by the Italian pancreatic research...
Background: the guidelines for the treatment of acute pancreatitis in Japan (hereinafter referred to as the Japanese guidelines) were first published in 2006.In 2008, the ...
it is reported that the incidence rate of acute pancreatitis all over the world is increasing. Although the quality of care, imaging examinationand treatment technology...
